5‐HT radioligands for human brain imaging with PET and SPECT
暂无分享,去创建一个
Victor W Pike | Gitte M Knudsen | V. Pike | G. Knudsen | D. Nutt | B. Kornum | David J Nutt | Birgitte R Kornum | Louise M Paterson | L. Paterson
[1] Nic Gillings,et al. Radiotracers for positron emission tomography imaging , 2013, Magnetic Resonance Materials in Physics, Biology and Medicine.
[2] V. Arango,et al. Ex vivo evaluation of the serotonin 1A receptor partial agonist [3H]CUMI‐101 in awake rats , 2011, Synapse.
[3] R. Davidson,et al. In vivo kinetics of [F‐18]MEFWAY: A comparison with [C‐11]WAY100635 and [F‐18]MPPF in the nonhuman primate , 2011, Synapse.
[4] L. Zimmer,et al. Effects of amyloid-β peptides on the serotoninergic 5-HT1A receptors in the rat hippocampus , 2011, Neurobiology of Aging.
[5] C. Halldin,et al. Quantitative Analysis of [11C]AZ10419369 Binding to 5-HT1B Receptors in Human Brain , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[6] N. Costes,et al. Brainstem changes in 5-HT1A receptor availability during migraine attack , 2011, Cephalalgia : an international journal of headache.
[7] R Todd Ogden,et al. In vivo Serotonin-Sensitive Binding of [11C]CUMI-101: A Serotonin 1A Receptor Agonist Positron Emission Tomography Radiotracer , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[8] C. Halldin,et al. Quantitative analysis of ( 11 C)AZ10419369 binding to 5-HT 1B receptors in human brain , 2011 .
[9] Anders Ettrup,et al. Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[10] J. Neumaier,et al. Reduced ventral striatal/ventral pallidal serotonin1B receptor binding potential in major depressive disorder , 2011, Psychopharmacology.
[11] Christine DeLorenzo,et al. In Vivo Quantification of Human Serotonin 1A Receptor Using 11C-CUMI-101, an Agonist PET Radiotracer , 2010, The Journal of Nuclear Medicine.
[12] Anders Ettrup,et al. Radiosynthesis and Evaluation of 11C-CIMBI-5 as a 5-HT2A Receptor Agonist Radioligand for PET , 2010, The Journal of Nuclear Medicine.
[13] J. Monti. The role of dorsal raphe nucleus serotonergic and non-serotonergic neurons, and of their receptors, in regulating waking and rapid eye movement (REM) sleep. , 2010, Sleep medicine reviews.
[14] Gitte M Knudsen,et al. Measuring Endogenous 5-HT Release by Emission Tomography: Promises and Pitfalls , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[15] Yiyun Huang,et al. Development of effective PET and SPECT imaging agents for the serotonin transporter: has a twenty-year journey reached its destination? , 2010, Current topics in medicinal chemistry.
[16] Christine A. Parker,et al. Evaluation of the in vivo ED50 for the PET Radioligand, [11C]GSK-215083, in Papio anubis , 2010, NeuroImage.
[17] L. Farde,et al. Fenfluramine‐induced serotonin release decreases [11C]AZ10419369 binding to 5‐HT1B‐receptors in the primate brain , 2010, Synapse.
[18] H. Diener,et al. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan – A randomised proof-of-concept trial , 2010, Cephalalgia : an international journal of headache.
[19] D. Le Bars,et al. Looking for a 5-HT7 radiotracer for positron emission tomography. , 2010, Bioorganic & medicinal chemistry letters.
[20] Terry L. Jernigan,et al. Seasonal Changes in Brain Serotonin Transporter Binding in Short Serotonin Transporter Linked Polymorphic Region-Allele Carriers but Not in Long-Allele Homozygotes , 2010, Biological Psychiatry.
[21] J Booij,et al. Investigating serotonergic function using positron emission tomography: overview and recent findings. , 2010, Current pharmaceutical design.
[22] Markus Piel,et al. 18F-labeling and evaluation of novel MDL 100907 derivatives as potential 5-HT2A antagonists for molecular imaging. , 2010, Nuclear medicine and biology.
[23] Diana Martinez,et al. A Comparative Evaluation of the Dopamine D2/3 Agonist Radiotracer [11C](−)-N-Propyl-norapomorphine and Antagonist [11C]Raclopride to Measure Amphetamine-Induced Dopamine Release in the Human Striatum , 2010, Journal of Pharmacology and Experimental Therapeutics.
[24] Claus Svarer,et al. Brain imaging of serotonin 4 receptors in humans with [11C]SB207145-PET , 2010, NeuroImage.
[25] Rainer Hinz,et al. Simplified quantification of 5-HT2A receptors in the human brain with [11C]MDL 100,907 PET and non-invasive kinetic analyses , 2010, NeuroImage.
[26] S. Ward,et al. Recent advances in the discovery of selective and non-selective 5-HT(1D) receptor ligands. , 2010, Current topics in medicinal chemistry.
[27] T. Jernigan,et al. Familial Risk for Mood Disorder and the Personality Risk Factor, Neuroticism, Interact in Their Association with Frontolimbic Serotonin 2A Receptor Binding , 2010, Neuropsychopharmacology.
[28] C. Svarer,et al. Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine , 2010, Schizophrenia Research.
[29] G. Simig,et al. Medicinal chemistry of 5-HT5A receptor ligands: a receptor subtype with unique therapeutical potential. , 2010, Current topics in medicinal chemistry.
[30] Richard E Carson,et al. High-resolution imaging of brain 5-HT 1B receptors in the rhesus monkey using [11C]P943. , 2010, Nuclear medicine and biology.
[31] Richard E Carson,et al. Kinetic Modeling of the Serotonin 5-HT1B Receptor Radioligand [11C]P943 in Humans , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[32] Yiyun Huang,et al. Serotonin 1B Receptor Imaging in Alcohol Dependence , 2009, Biological Psychiatry.
[33] S. Zoghbi,et al. Evaluation of [11C]S14506 and [18F]S14506 in rat and monkey as agonist PET radioligands for brain 5-HT1A receptors , 2010 .
[34] G. Reynolds,et al. Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms. , 2010, Pharmacology & therapeutics.
[35] S. Zoghbi,et al. Evaluation of [C]S14506 and [F]S14506 in rat and monkey as agonist PET radioligands for brain 5-HT(1A) receptors. , 2010, Current radiopharmaceuticals.
[36] Luc Zimmer,et al. [18F]F15599, a novel 5-HT1A receptor agonist, as a radioligand for PET neuroimaging , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[37] Ying-Kai Fu,et al. Biodistribution, toxicity and radiation dosimetry studies of the serotonin transporter radioligand 4-[18F]-ADAM in rats and monkeys , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[38] M. Millan,et al. Differential influence of selective 5-HT5A vs 5-HT1A, 5-HT1B, or 5-HT2C receptor blockade upon light-induced phase shifts in circadian activity rhythms: Interaction studies with citalopram , 2009, European Neuropsychopharmacology.
[39] Z. Bhagwagar,et al. The 5-HT1B receptor: a novel target for the pathophysiology of depression. , 2009, Current drug targets.
[40] O. Paulson,et al. Gender and the use of hormonal contraception in women are not associated with cerebral cortical 5-HT 2A receptor binding , 2009, Neuroscience.
[41] Rupert Lanzenberger,et al. The Serotonin-1A Receptor in Anxiety Disorders , 2009, Biological Psychiatry.
[42] M. Macavoy,et al. Regional distribution and behavioral correlates of 5-HT2A receptors in Alzheimer's disease with [18F]deuteroaltanserin and PET , 2009, Psychiatry Research: Neuroimaging.
[43] Donald F. Smith,et al. Molecular tools for assessing human depression by positron emission tomography , 2009, European Neuropsychopharmacology.
[44] Lars Farde,et al. Genetic Variation in Brain-Derived Neurotrophic Factor Is Associated with Serotonin Transporter but Not Serotonin-1A Receptor Availability in Men , 2009, Biological Psychiatry.
[45] Victor W Pike,et al. PET radiotracers: crossing the blood-brain barrier and surviving metabolism. , 2009, Trends in pharmacological sciences.
[46] Ramin V. Parsey,et al. Positron Emission Tomography Quantification of Serotonin-1A Receptor Binding in Medication-Free Bipolar Depression , 2009, Biological Psychiatry.
[47] A. Gjedde,et al. Parametric Mapping of 5HT1A Receptor Sites in the Human Brain with the Hypotime Method: Theory and Normal Values , 2009, Journal of Nuclear Medicine.
[48] R Todd Ogden,et al. Reported childhood abuse is associated with low serotonin transporter binding in vivo in major depressive disorder , 2009, Synapse.
[49] P. Moayyedi,et al. Efficacy of 5-HT3 Antagonists and 5-HT4 Agonists in Irritable Bowel Syndrome: Systematic Review and Meta-Analysis , 2009, The American Journal of Gastroenterology.
[50] L. Mrzljak,et al. [N-methyl-3H3]AZ10419369 Binding to the 5-HT1B Receptor: In Vitro Characterization and in Vivo Receptor Occupancy , 2009, Journal of Pharmacology and Experimental Therapeutics.
[51] Claus Svarer,et al. High familial risk for mood disorder is associated with low dorsolateral prefrontal cortex serotonin transporter binding , 2009, NeuroImage.
[52] Wen-Sheng Huang,et al. An improved synthesis of 4-[18F]-ADAM, a potent serotonin transporter imaging agent. , 2009, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[53] Claus Svarer,et al. Kinetic Modeling of 11C-SB207145 Binding to 5-HT4 Receptors in the Human Brain In Vivo , 2009, Journal of Nuclear Medicine.
[54] Olaf B. Paulson,et al. Brain serotonin 2A receptor binding: Relations to body mass index, tobacco and alcohol use , 2009, NeuroImage.
[55] Xianzhong Zhang,et al. Synthesis and biological evaluation of 99mTc-HEDTA/HYNIC-MPP4 complex for 5-HT1A receptor imaging , 2009 .
[56] M. Piel,et al. Preliminary in vivo and ex vivo evaluation of the 5-HT2A imaging probe [(18)F]MH.MZ. , 2009, Nuclear medicine and biology.
[57] Christer Halldin,et al. 5-HT1A receptor and 5-HTT binding during the menstrual cycle in healthy women examined with [11C] WAY100635 and [11C] MADAM PET , 2009, Psychiatry Research: Neuroimaging.
[58] Markus Piel,et al. Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET. , 2009, Bioorganic & medicinal chemistry.
[59] Stuart C. Sealfon,et al. Psychedelics and schizophrenia , 2009, Trends in Neurosciences.
[60] Morten L. Kringelbach,et al. The personality trait openness is related to cerebral 5-HTT levels , 2009, NeuroImage.
[61] B. Långström,et al. Species Differences in Blood-Brain Barrier Transport of Three Positron Emission Tomography Radioligands with Emphasis on P-Glycoprotein Transport , 2009, Drug Metabolism and Disposition.
[62] A. Bagić,et al. 18F‐FCWAY and 18F‐FDG PET in MRI‐negative temporal lobe epilepsy , 2009, Epilepsia.
[63] P. Heusler,et al. Signal transduction and functional selectivity of F15599, a preferential post‐synaptic 5‐HT1A receptor agonist , 2009, British journal of pharmacology.
[64] Flemming Andersen,et al. Evaluation of the Novel 5-HT4 Receptor PET Ligand [11C]SB207145 in the Göttingen Minipig , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[65] Ren-Shyan Liu,et al. Validation of 4-[18F]-ADAM as a SERT imaging agent using micro-PET and autoradiography , 2007, NeuroImage.
[66] Young-Don Hong,et al. Novel 99m Tc(CO) 3 Complexes with WAY-100635 Moiety for the Development of 5-HT 1A Receptor lmaging Agent , 2009 .
[67] H. Coenen,et al. Synthesis, labelling and first evaluation of [18F]R91150 as a serotonin 5‐HT2A receptor antagonist for PET , 2009 .
[68] Søren Holm,et al. Longitudinal assessment of cerebral 5-HT2A receptors in healthy elderly volunteers: an [18F]-altanserin PET study , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[69] M. Laruelle,et al. Evaluation of the novel 5-HT6 receptor radioligand, [11C]GSK-215083 in human , 2008, NeuroImage.
[70] N. Costes,et al. Interictal Brain 5-HT1A Receptors Binding in Migraine Without Aura: A 18F-MPPF-PET Study , 2008, Cephalalgia : an international journal of headache.
[71] C. Svarer,et al. Reduced 5-HT2A receptor binding in patients with mild cognitive impairment , 2008, Neurobiology of Aging.
[72] F. de Vos,et al. In vivo evaluation in rodents of [(123)I]-3-I-CO as a potential SPECT tracer for the serotonin 5-HT(2A) receptor. , 2008, Nuclear medicine and biology.
[73] R. Bell,et al. The role of 5-HT3 receptors in drug abuse and as a target for pharmacotherapy. , 2008, CNS & neurological disorders drug targets.
[74] N. Costes,et al. Comorbidity between temporal lobe epilepsy and depression: a [18F]MPPF PET study. , 2008, Brain : a journal of neurology.
[75] Xianzhong Zhang,et al. N-[3-[4-(2-methoxyphenyl) piperaziny-1-yl]propyl]cyclam: synthesized as a potential 5-HT1A receptor ligand and labelled with 99mTc-nitrido core , 2008 .
[76] Charles A. Marsden,et al. A role for the 5-HT1A, 5-HT4 and 5-HT6 receptors in learning and memory , 2008 .
[77] D. Nutt,et al. Serotonin 5-HT1A receptor binding in people with panic disorder: positron emission tomography study. , 2008, The British journal of psychiatry : the journal of mental science.
[78] Claus Svarer,et al. Cortical and Subcortical 5-HT2A Receptor Binding in Neuroleptic-Naive First-Episode Schizophrenic Patients , 2008, Neuropsychopharmacology.
[79] Alessandra Gorini,et al. In vivo PET study of 5HT2A serotonin and D2 dopamine dysfunction in drug-naive obsessive-compulsive disorder , 2008, NeuroImage.
[80] A. Luxen,et al. Cyclosporine, a P-glycoprotein modulator, increases [18F]MPPF uptake in rat brain and peripheral tissues: microPET and ex vivo studies , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[81] G. Hutchins,et al. Synthesis of new carbon-11 labeled benzoxazole derivatives for PET imaging of 5-HT(3) receptor. , 2008, European journal of medicinal chemistry.
[82] Christer Halldin,et al. [11C]AZ10419369: A selective 5-HT1B receptor radioligand suitable for positron emission tomography (PET). Characterization in the primate brain , 2008, NeuroImage.
[83] Laurent Descarries,et al. Decreased [18F]MPPF Binding Potential in the Dorsal Raphe Nucleus After a Single Oral Dose of Fluoxetine: A Positron-Emission Tomography Study in Healthy Volunteers , 2008, Biological Psychiatry.
[84] M N Smolka,et al. Anxiety is associated with reduced central serotonin transporter availability in unmedicated patients with unipolar major depression: a [11C]DASB PET study , 2008, Molecular Psychiatry.
[85] J. Passchier,et al. Synthesis and Evaluation of [11C]SB207145 as the First In Vivo Serotonin 5-HT4 Receptor Radioligand for PET Imaging in Man , 2008 .
[86] Wen-Sheng Huang,et al. An automated synthesis of N,N-dimethyl-2-(2-amino-4-[18F]fluorophenylthio)benzylamine (4-[18F]-ADAM) for imaging serotonin transporters. , 2008, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[87] A. Stunkard,et al. 123I-ADAM SPECT imaging of serotonin transporter binding in patients with Night Eating Syndrome: A preliminary report , 2008, Psychiatry Research: Neuroimaging.
[88] Claus Svarer,et al. The 5-HT2A receptor binding pattern in the human brain is strongly genetically determined , 2008, NeuroImage.
[89] R Todd Ogden,et al. Modeling Considerations for 11C-CUMI-101, an Agonist Radiotracer for Imaging Serotonin 1A Receptor In Vivo with PET , 2008, Journal of Nuclear Medicine.
[90] K. Hornik,et al. Changes in Thalamus–Hypothalamus Serotonin Transporter Availability during Clomipramine Administration in Patients with Obsessive–Compulsive Disorder , 2008, Neuropsychopharmacology.
[91] Olaf B. Paulson,et al. Frontolimbic Serotonin 2A Receptor Binding in Healthy Subjects Is Associated with Personality Risk Factors for Affective Disorder , 2008, Biological Psychiatry.
[92] Masami Nishikawa,et al. An index of 5-HT synthesis changes during early antidepressant treatment: α-[11C]methyl-l-tryptophan PET study , 2008, Neurochemistry International.
[93] G. Knudsen,et al. Total synthesis and evaluation of [18F]MHMZ. , 2008, Bioorganic & medicinal chemistry letters.
[94] K. Leenders,et al. Decreased blood–brain barrier P-glycoprotein function in the progression of Parkinson’s disease, PSP and MSA , 2008, Journal of Neural Transmission.
[95] Dennis L. Murphy,et al. Targeting the murine serotonin transporter: insights into human neurobiology , 2008, Nature Reviews Neuroscience.
[96] C. Svarer,et al. Evaluation of the Serotonin Transporter Ligand 123I-ADAM for SPECT Studies on Humans , 2008, Journal of Nuclear Medicine.
[97] Christer Halldin,et al. Sex differences in the serotonin 1A receptor and serotonin transporter binding in the human brain measured by PET , 2008, NeuroImage.
[98] T. Tasdizen,et al. Realizing the potential of positron emission tomography with 18F-fluorodeoxyglucose to improve the treatment of Alzheimer’s disease , 2008, Alzheimer's & Dementia.
[99] C. Marsden,et al. A role for the 5-HT(1A), 5-HT4 and 5-HT6 receptors in learning and memory. , 2008, Trends in pharmacological sciences.
[100] G. Remington. Alterations of dopamine and serotonin transmission in schizophrenia. , 2008, Progress in brain research.
[101] B. Långström,et al. Species differences in blood-brain barrier transport of three PET radioligands with emphasis on P-glycoprotein transport , 2008 .
[102] J. Prickaerts,et al. The dorsal raphe nucleus and serotonin: implications for neuroplasticity linked to major depression and Alzheimer's disease. , 2008, Progress in brain research.
[103] A. Antonini,et al. Loss of thalamic serotonin transporters in early drug-naïve Parkinson’s disease patients is associated with tremor: an [123I]β-CIT SPECT study , 2008, Journal of Neural Transmission.
[104] P. Cowen,et al. 5-HTT binding in recovered depressed patients and healthy volunteers: a positron emission tomography study with [11C]DASB. , 2007, The American journal of psychiatry.
[105] C. Halldin,et al. PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram. , 2007, The international journal of neuropsychopharmacology.
[106] Gregor Hasler,et al. 5-HT1A Receptor Binding in Temporal Lobe Epilepsy Patients With and Without Major Depression , 2007, Biological Psychiatry.
[107] Manfred Göthert,et al. 5-HT Receptor Regulation of Neurotransmitter Release , 2007, Pharmacological Reviews.
[108] D. Le Bars,et al. Synthesis and biological evaluation in rat and cat of [18F]12ST05 as a potential 5-HT6 PET radioligand. , 2007, Nuclear medicine and biology.
[109] Marianne Patt,et al. Synthesis procedure for routine production of 2-[18F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[18F]F-A-85380). , 2007, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[110] W. Maier,et al. 5-HT2A receptor density is decreased in the at-risk mental state , 2007, Psychopharmacology.
[111] Christer Halldin,et al. A PET study on regional coexpression of 5-HT1A receptors and 5-HTT in the human brain , 2007, Psychopharmacology.
[112] F. Colpaert,et al. High-efficacy 5-HT1A agonists for antidepressant treatment: a renewed opportunity. , 2007, Journal of medicinal chemistry.
[113] A. Vighetto,et al. Up-regulation of hippocampal serotonin metabolism in mild cognitive impairment , 2007, Neurology.
[114] J. Mann,et al. PET tracers for 5-HT(1A) receptors and uses thereof. , 2007, Drug discovery today.
[115] A. Heinz,et al. Reduced availability of serotonin transporters in obsessive-compulsive disorder correlates with symptom severity – a [11C]DASB PET study , 2007, Journal of Neural Transmission.
[116] R. Buchert,et al. Ecstasy-induced reduction of the availability of the brain serotonin transporter as revealed by [11C](+)McN5652-PET and the multi-linear reference tissue model: loss of transporters or artifact of tracer kinetic modelling? , 2007, Journal of psychopharmacology.
[117] G. Slegers,et al. Differences of cortical 5-HT2A receptor binding index with SPECT in subtypes of anorexia nervosa: relationship with personality traits? , 2007, Journal of psychiatric research.
[118] Anthonin Reilhac,et al. Test–Retest Reproducibility of 18F-MPPF PET in Healthy Humans: A Reliability Study , 2007, Journal of Nuclear Medicine.
[119] F. Yasuno,et al. Quantification of serotonin 5‐HT1A receptors in humans with [11C](R)‐(−)‐RWAY: Radiometabolite(s) likely confound brain measurements , 2007, Synapse.
[120] H. Möller,et al. [I-123] ADAM and SPECT in patients with borderline personality disorder and healthy control subjects. , 2007, Journal of psychiatry & neuroscience : JPN.
[121] Jeih-San Liow,et al. Disulfiram Inhibits Defluorination of 18F-FCWAY, Reduces Bone Radioactivity, and Enhances Visualization of Radioligand Binding to Serotonin 5-HT1A Receptors in Human Brain , 2007, Journal of Nuclear Medicine.
[122] H. Wikström,et al. Synthesis and initial evaluation of [11C](R)-RWAY in monkey—a new, simply labeled antagonist radioligand for imaging brain 5-HT1A receptors with PET , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[123] Alan A. Wilson,et al. Serotonin transporter occupancy of high-dose selective serotonin reuptake inhibitors during major depressive disorder measured with [11C]DASB positron emission tomography , 2007, Psychopharmacology.
[124] Carolyn C. Meltzer,et al. Exaggerated 5-HT1A but Normal 5-HT2A Receptor Activity in Individuals Ill with Anorexia Nervosa , 2007, Biological Psychiatry.
[125] Wolfgang Wadsak,et al. Reduced Serotonin-1A Receptor Binding in Social Anxiety Disorder , 2007, Biological Psychiatry.
[126] Bengt Långström,et al. 5-Hydroxy-l-[β-11C]tryptophan versus α-[11C]Methyl-l-tryptophan for Positron Emission Tomography Imaging of Serotonin Synthesis Capacity in the Rhesus Monkey Brain , 2007 .
[127] Claus Svarer,et al. Cerebral 5-HT2A receptor binding is increased in patients with Tourette's syndrome. , 2007, The international journal of neuropsychopharmacology.
[128] G. Slegers,et al. Synthesis and in vivo evaluation in mice of [123I]‐(4‐fluorophenyl)[1‐(3‐iodophenethyl)piperidin‐4‐yl]methanone as a potential SPECT‐tracer for the serotonin 5‐HT2A receptor , 2007 .
[129] Luc Zimmer,et al. [18F]MPPF as a tool for the in vivo imaging of 5-HT1A receptors in animal and human brain , 2007, Neuropharmacology.
[130] Yan Huang,et al. Preparation and biodistribution of 99mTc-tricarbonyl complex with 4-[(2-methoxyphenyl)piperazin-1-yl]-dithioformate as a potential 5-HT1A receptor imaging agent. , 2007, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[131] R. Vanninen,et al. Reduced midbrain serotonin transporter availability in drug-naïve patients with depression measured by SERT-specific [123I] nor-β-CIT SPECT imaging , 2007, Psychiatry Research: Neuroimaging.
[132] Vincent J Cunningham,et al. Validation of a Tracer Kinetic Model for the Quantification of 5-HT2A Receptors in Human Brain with [11C]MDL 100,907 , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[133] A. Villringer,et al. Increased serotonin transporter availability in the brainstem of migraineurs , 2006, Clinical Neurophysiology.
[134] B. Långström,et al. 5-Hydroxy-L-[beta-11C]tryptophan versus alpha-[11C]methyl-L-tryptophan for positron emission tomography imaging of serotonin synthesis capacity in the rhesus monkey brain. , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[135] Jeih-San Liow,et al. PET [11C]DASB imaging of serotonin transporters in patients with alcoholism. , 2007, Alcoholism, clinical and experimental research.
[136] M. Beauregard,et al. In vivo measurements of brain trapping of C-labelled alpha-methyl-L-tryptophan during acute changes in mood states. , 2007, Journal of psychiatry & neuroscience : JPN.
[137] Tim B. Dyrby,et al. Reproducibility of 5-HT2A receptor measurements and sample size estimations with [18F]altanserin PET using a bolus/infusion approach , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[138] Rupert Lanzenberger,et al. Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study , 2007, Psychopharmacology.
[139] Ramin V. Parsey,et al. Synthesis and in vivo evaluation of a novel 5-HT1A receptor agonist radioligand [O-methyl-11C]2-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)dione in nonhuman primates , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[140] F. Yasuno,et al. Quantification of serotonin 5-HT1A receptors in monkey brain with [11C](−)-RWAY , 2006, NeuroImage.
[141] J. Passchier,et al. [11C]GSK224558 as a potential PET ligand for the delineation of 5-HT6 receptors , 2006, NeuroImage.
[142] J. Hirvonen,et al. Measurement of serotonin 5-HT1A receptor binding using positron emission tomography and [carbonyl-11C]WAY-100635—considerations on the validity of cerebellum as a reference region , 2006, NeuroImage.
[143] F. Yasuno,et al. Quantification of serotonin 5‐HT1A receptors in monkey brain with [11C](R)‐(−)‐RWAY , 2006, Synapse.
[144] M. Reimold,et al. Occupancy of dopamine D1, D2 and serotonin2A receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol , 2006, Psychopharmacology.
[145] S. Jang,et al. Highly Efficient Synthesis and Imaging Studies of an Arylpiperazine Derivative as a 5-HT1A Receptor Imaging Agent , 2006 .
[146] Iluminada Corripio,et al. Serotonin transporter occupancy induced by paroxetine in patients with major depression disorder: a 123I-ADAM SPECT study , 2006, Psychopharmacology.
[147] Jogeshwar Mukherjee,et al. Synthesis and biologic evaluation of a novel serotonin 5-HT1A receptor radioligand, 18F-labeled mefway, in rodents and imaging by PET in a nonhuman primate. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[148] R. Vanninen,et al. Midbrain binding of [123I]nor-β-CIT in atypical depression , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[149] R. Lanzenberger,et al. In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram , 2006, Psychopharmacology.
[150] Christer Halldin,et al. Measurement of serotonin transporter binding with PET and [11C]MADAM: A test–retest reproducibility study , 2006, Synapse.
[151] Zubin Bhagwagar,et al. Increased 5-HT(2A) receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [(11)C]MDL 100,907. , 2006, The American journal of psychiatry.
[152] Bryan L. Roth,et al. WAY-100635 is a potent dopamine D4 receptor agonist , 2006, Psychopharmacology.
[153] Masanori Ichise,et al. Serotonin Transporter Binding in Bipolar Disorder Assessed using [11C]DASB and Positron Emission Tomography , 2006, Biological Psychiatry.
[154] Philippe Marin,et al. Neuronal 5-HT metabotropic receptors: fine-tuning of their structure, signaling, and roles in synaptic modulation , 2006, Cell and Tissue Research.
[155] A. Luxen,et al. Radiochemical synthesis and tissue distribution of p-[18F]DMPPF, a new 5-HT1A ligand for PET, in rats. , 2006, Nuclear Medicine and Biology.
[156] Ying Ma,et al. Synthesis and in vivo biodistribution of F-18 labeled 3-cis-, 3-trans-, 4-cis-, and 4-trans-fluorocyclohexane derivatives of WAY 100635. , 2006, Bioorganic & medicinal chemistry.
[157] G. Nucci,et al. Characterization of the SPECT 5-HT2A receptor ligand 123I-R91150 in healthy volunteers: part 2--ketanserin displacement. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[158] V. Cunningham,et al. Characterization of the SPECT 5-HT2A receptor ligand 123I-R91150 in healthy volunteers: Part 1--pseudoequilibrium interval and quantification methods. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[159] M. Millan. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. , 2006, Pharmacology & therapeutics.
[160] Ramin V. Parsey,et al. Acute Occupancy of Brain Serotonin Transporter by Sertraline as Measured by [11C]DASB and Positron Emission Tomography , 2006, Biological Psychiatry.
[161] R. V. Van Heertum,et al. Synthesis, in vitro and in vivo evaluation of [O-methyl-11C] 2-{4-[4-(3-methoxyphenyl)piperazin-1-yl]-butyl}-4-methyl-2H-[1,2,4]-triazine-3,5-dione: a novel agonist 5-HT1A receptor PET ligand. , 2006, Bioorganic & medicinal chemistry letters.
[162] David C. Reutens,et al. Increased serotonin receptor availability in human sleep: Evidence from an [18F]MPPF PET study in narcolepsy , 2006, NeuroImage.
[163] Masanori Ichise,et al. PET imaging of serotonin transporters with [11C]DASB: test-retest reproducibility using a multilinear reference tissue parametric imaging method. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[164] Jeih-San Liow,et al. PET imaging of brain 5-HT1A receptors in rat in vivo with 18F-FCWAY and improvement by successful inhibition of radioligand defluorination with miconazole. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[165] R. V. Van Heertum,et al. Synthesis and in vivo validation of [O-methyl-11C]2-{4-[4-(7-methoxynaphthalen-1-yl)piperazin- 1-yl]butyl}-4-methyl-2H-[1,2,4]triazine-3,5-dione: a novel 5-HT1A receptor agonist positron emission tomography ligand. , 2006, Journal of medicinal chemistry.
[166] C. Daumas-Duport,et al. Evaluation of Drug Penetration into the Brain: A Double Study by in Vivo Imaging with Positron Emission Tomography and Using an in Vitro Model of the Human Blood-Brain Barrier , 2006, Journal of Pharmacology and Experimental Therapeutics.
[167] W J Riedel,et al. Serotonin and human cognitive performance. , 2006, Current pharmaceutical design.
[168] Jörg Steinbach,et al. [11C]SMe-ADAM, an imaging agent for the brain serotonin transporter: synthesis, pharmacological characterization and microPET studies in rats. , 2006, Nuclear medicine and biology.
[169] R. Vanninen,et al. Midbrain binding of [123I]nor-beta-CIT in atypical depression. , 2006, Progress in neuro-psychopharmacology & biological psychiatry.
[170] S. Tanada,et al. A dose-finding study of duloxetine based on serotonin transporter occupancy , 2006, Psychopharmacology.
[171] R. Felix,et al. Imaging of serotonin transporters and its blockade by citalopram in patients with major depression using a novel SPECT ligand [123I]-ADAM , 2006, Journal of Neural Transmission.
[172] M. Garcia-Alloza,et al. Cholinergic–serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer’s disease , 2005, Neuropsychologia.
[173] Nic Gillings,et al. Binding characteristics of the 5‐HT2A receptor antagonists altanserin and MDL 100907 , 2005, Synapse.
[174] Berend Olivier,et al. 5-HT1B receptors and aggression: a review. , 2005, European journal of pharmacology.
[175] Denis Guilloteau,et al. [11C]MADAM, a new serotonin transporter radioligand characterized in the monkey brain by PET , 2005, Synapse.
[176] Nicolas Costes,et al. A 18F-MPPF PET normative database of 5-HT1A receptor binding in men and women over aging. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[177] Michael Wagner,et al. Decreased prefrontal 5-HT2A receptor binding in subjects at enhanced risk for schizophrenia , 2005, Anatomy and Embryology.
[178] C. Halldin,et al. Quantification of 11C-MADAM binding to the serotonin transporter in the human brain. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[179] Zsolt Szabo,et al. Quantitative PET Studies of the Serotonin Transporter in MDMA Users and Controls Using [11C]McN5652 and [11C]DASB , 2005, Neuropsychopharmacology.
[180] Claus Svarer,et al. Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei. , 2005, The international journal of neuropsychopharmacology.
[181] K. Erlandsson,et al. Measuring SSRI occupancy of SERT using the novel tracer [123I]ADAM: a SPECT validation study , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[182] Radiolabelling and in vivo evaluation of [11C]GSK215083 as potential PET radioligand for the 5-HT6 receptor in the porcine brain , 2005 .
[183] D. Puigdemont,et al. SPECT of serotonin transporters using 123I-ADAM: optimal imaging time after bolus injection and long-term test-retest in healthy volunteers. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[184] Richard E Carson,et al. 5-HT 1A receptors are reduced in temporal lobe epilepsy after partial-volume correction. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[185] Victoria Arango,et al. Regional Heterogeneity of 5-HT1A Receptors in Human Cerebellum as Assessed by Positron Emission Tomography , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[186] Yiyun Huang,et al. Serotonin Transporter Availability in Patients with Schizophrenia: A Positron Emission Tomography Imaging Study with [11C]DASB , 2005, Biological Psychiatry.
[187] A. Alavi,et al. 123I-ADAM binding to serotonin transporters in patients with major depression and healthy controls: a preliminary study. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[188] Carolyn C. Meltzer,et al. Serotonin alterations in anorexia and bulimia nervosa: New insights from imaging studies , 2005, Physiology & Behavior.
[189] Marco Leyton,et al. Brain regional alpha-[11C]methyl-L-tryptophan trapping correlates with post-mortem tissue serotonin content and [11C]5-hydroxytryptophan accumulation. , 2005, The international journal of neuropsychopharmacology.
[190] O. Muzik,et al. Synthesis procedure for routine production of [carbonyl-11C]desmethyl-WAY-100635. , 2005, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[191] Mark Slifstein,et al. Brain serotonin transporter distribution in subjects with impulsive aggressivity: a positron emission study with [11C]McN 5652. , 2005, The American journal of psychiatry.
[192] D. Doudet,et al. Electroconvulsive shock decreases binding to 5-HT2 receptors in nonhuman primates: An in vivo positron emission tomography study with [18F]setoperone , 2005, Biological Psychiatry.
[193] G. Slegers,et al. Synthesis, radiosynthesis and in vivo evaluation in mice of [123I]-(4-fluorophenyl) {1-[2-(4-iodophenyl)ethyl]piperidin-4-yl}methanone for visualization of the 5-HT2A receptor with SPECT. , 2005, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[194] J. Krushinski,et al. [3H]LY334370, a novel radioligand for the 5-HT1F receptor. II. Autoradiographic localization in rat, guinea pig, monkey and human brain , 2005, Naunyn-Schmiedeberg's Archives of Pharmacology.
[195] J. Zgombick,et al. [3H]LY334370, a novel radioligand for the 5-HT1F receptor. I. In vitro characterization of binding properties , 2005, Naunyn-Schmiedeberg's Archives of Pharmacology.
[196] B. Harrison,et al. 4-(2-Aminoethoxy)-N-(phenylsulfonyl)indoles as novel 5-HT6 receptor ligands. , 2005, Bioorganic & medicinal chemistry letters.
[197] W. Drevets,et al. No change in serotonin type 1A receptor binding in patients with posttraumatic stress disorder. , 2005, The American journal of psychiatry.
[198] Christer Halldin,et al. 5-HT2 and D2 dopamine receptor occupancy in the living human brain , 1993, Psychopharmacology.
[199] Clinton D Kilts,et al. Synthesis and characterization of EADAM: a selective radioligand for mapping the brain serotonin transporters by positron emission tomography. , 2005, Nuclear medicine and biology.
[200] J. Menchón,et al. High affinity [3H]imipramine and [3H]paroxetine binding sites in suicide brains , 2005, Journal of Neural Transmission.
[201] B. Långström,et al. Pyridoxine effect on synthesis rate of serotonin in the monkey brain measured with positron emission tomography , 2005, Journal of Neural Transmission / General Section JNT.
[202] J. Kornhuber,et al. SPECT imaging of dopamine and serotonin transporters with [123I]β-CIT. Binding kinetics in the human brain , 2005, Journal of Neural Transmission / General Section JNT.
[203] B. Långström,et al. Positron emission tomographic studies on aromatic L-amino acid decarboxylase activity in vivo for L-dopa and 5-hydroxy-L-tryptophan in the monkey brain , 2005, Journal of Neural Transmission / General Section JNT.
[204] C. Halldin,et al. High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET , 2005, Psychopharmacology.
[205] J. Tiihonen,et al. Reduced brain serotonin transporter binding in patients with panic disorder , 2004, Psychiatry Research: Neuroimaging.
[206] Sylvain Houle,et al. Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. , 2004, Archives of general psychiatry.
[207] J. Greenberg,et al. Synthesis and evaluation of N,N-dimethyl-2-(2-amino-5-[18F]fluorophenylthio)benzylamine (5-[18F]-ADAM) as a serotonin transporter imaging agent. , 2004, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[208] M. Mintun,et al. Decreased Hippocampal 5-HT2A Receptor Binding in Older Depressed Patients Using [18F]Altanserin Positron Emission Tomography , 2004, Neuropsychopharmacology.
[209] J. Tiihonen,et al. SPECT imaging of serotonin transporter binding in patients with generalized anxiety disorder , 2004, European Archives of Psychiatry and Clinical Neuroscience.
[210] Yiyun Huang,et al. The new PET imaging agent [11C]AFE is a selective serotonin transporter ligand with fast brain uptake kinetics. , 2004, Nuclear medicine and biology.
[211] Alan A. Wilson,et al. Tryptophan depletion and serotonin loss in selective serotonin reuptake inhibitor–treated depression: An [18F] MPPF positron emission tomography study , 2004, Biological Psychiatry.
[212] Y. Sari. Serotonin1B receptors: from protein to physiological function and behavior , 2004, Neuroscience & Biobehavioral Reviews.
[213] J. Sutcliffe,et al. Functional, molecular and pharmacological advances in 5-HT7 receptor research. , 2004, Trends in pharmacological sciences.
[214] G. Slegers,et al. Synthesis, radiosynthesis and preliminary in vivo evaluation of [123I]-(4-fluorophenyl) {1-[2-(2-iodophenyl)ethyl]piperidin-4-yl}methanone, a potential 5-HT2A-antagonist for SPECT brain imaging , 2004 .
[215] Yiyun Huang,et al. A PET imaging agent with fast kinetics: synthesis and in vivo evaluation of the serotonin transporter ligand [11C]2-[2-dimethylaminomethylphenylthio)]-5-fluorophenylamine ([11C]AFA). , 2004, Nuclear medicine and biology.
[216] Mark Slifstein,et al. In vivo vulnerability to competition by endogenous dopamine: Comparison of the D2 receptor agonist radiotracer (–)‐N‐[11C]propyl‐norapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C]‐raclopride , 2004, Synapse.
[217] Lisa Weissfeld,et al. Altered 5-HT2A Receptor Binding after Recovery from Bulimia-Type Anorexia Nervosa: Relationships to Harm Avoidance and Drive for Thinness , 2004, Neuropsychopharmacology.
[218] Cheng-Yu Chen,et al. Imaging serotonin transporters with 123I-ADAM brain SPECT in healthy non-human primates , 2004, Nuclear medicine communications.
[219] S. Kapur,et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. , 2004, The American journal of psychiatry.
[220] A. Alavi,et al. Biodistribution and imaging with (123)I-ADAM: a serotonin transporter imaging agent. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[221] François Mauguière,et al. 5-HT1A receptor binding and intracerebral activity in temporal lobe epilepsy: an [18F]MPPF-PET study. , 2004, Brain : a journal of neurology.
[222] Mark Slifstein,et al. Comparative evaluation of serotonin transporter radioligands 11C-DASB and 11C-McN 5652 in healthy humans. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[223] J. Boutin,et al. The Emergence of Selective 5-HT2B Antagonists Structures, Activities and Potential Therapeutic Applications [General Reviews] , 2004 .
[224] Andrei G. Vlassenko,et al. Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography , 2004, Biological Psychiatry.
[225] J. Bockaert,et al. 5-HT4 receptors. , 2004, Current drug targets. CNS and neurological disorders.
[226] C. Marsden,et al. 5-ht6 receptors. , 2004, Current drug targets. CNS and neurological disorders.
[227] L. Lanfumey,et al. 5-HT1 receptors. , 2004, Current drug targets. CNS and neurological disorders.
[228] J. Hagan,et al. 5-HT7 receptors. , 2004, Current drug targets. CNS and neurological disorders.
[229] J. Leysen,et al. 5-HT2 receptors. , 2004, Current drug targets. CNS and neurological disorders.
[230] D. Nelson,et al. 5-HT5 receptors. , 2004, Current drug targets. CNS and neurological disorders.
[231] Peter Herscovitch,et al. Reduced Serotonin Type 1A Receptor Binding in Panic Disorder , 2004, The Journal of Neuroscience.
[232] C. Halldin,et al. In vitro and in vivo characterisation of nor-β-CIT: a potential radioligand for visualisation of the serotonin transporter in the brain , 1997, European Journal of Nuclear Medicine.
[233] J. Leysen,et al. Initial evaluation of123I-5-I-R91150, a selective 5-HT2A ligand for single-photon emission tomography, in healthy human subjects , 1997, European Journal of Nuclear Medicine.
[234] A. Carr,et al. [3H]MDL 100,907: a novel selective 5-HT2A receptor ligand , 1996, Naunyn-Schmiedeberg's Archives of Pharmacology.
[235] André Luxen,et al. Multicompartmental study of fluorine-18 altanserin binding to brain 5HT2 receptors in humans using positron emission tomography , 1994, European Journal of Nuclear Medicine.
[236] H. Wikström,et al. The pyridinyl-6 position of WAY-100635 as a site for radiofluorination--effect on 5-HT1A receptor radioligand behavior in vivo. , 2004, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.
[237] J. Boutin,et al. The emergence of selective 5-HT 2B antagonists structures, activities and potential therapeutic applications. , 2004, Mini reviews in medicinal chemistry.
[238] Joel S Karp,et al. N,N-dimethyl-2-(2-amino-4-(18)F-fluorophenylthio)-benzylamine (4-(18)F-ADAM): an improved PET radioligand for serotonin transporters. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[239] O Sabri,et al. In vivo Measurement of the Serotonin Transporter with (S)-([18F]fluoromethyl)-(+)-McN5652 , 2003, Neuropsychopharmacology.
[240] S. Hume,et al. Radioiodinated SB 207710 as a radioligand in vivo: imaging of brain 5-HT4 receptors with SPET , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[241] M. Millan,et al. The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways , 2003, Journal of Pharmacology and Experimental Therapeutics.
[242] Claus Svarer,et al. Quantification of 5-HT2A Receptors in the Human Brain Using [18F]Altanserin-PET and the Bolus/Infusion Approach , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[243] John P Seibyl,et al. Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal women. , 2003, The American journal of psychiatry.
[244] C. Halldin,et al. Synthesis of a [6-pyridinyl-18F]-labelled fluoro derivative of WAY-100635 as a candidate radioligand for brain 5-HT1A receptor imaging with PET. , 2003, Bioorganic & medicinal chemistry.
[245] J. Korf,et al. Imaging of the 5-HT2A system: age-, gender-, and Alzheimer’s disease-related findings , 2003, Neurobiology of Aging.
[246] G. Slegers,et al. Prefrontal 5-HT2a receptor binding index, hopelessness and personality characteristics in attempted suicide. , 2003, Journal of affective disorders.
[247] N. Volkow,et al. Positron emission tomography and single-photon emission computed tomography in substance abuse research. , 2003, Seminars in nuclear medicine.
[248] W C Eckelman,et al. PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy , 2003, Neurology.
[249] Koen Van Laere,et al. Decreased 5-HT2a receptor binding in patients with anorexia nervosa. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[250] C. Kikuchi,et al. Tetrahydrothienopyridylbutyl‐tetrahydrobenzindoles: New Selective Ligands of the 5‐HT7 Receptor. , 2003 .
[251] Denis Guilloteau,et al. Pharmacological Characterization ofN,N-Dimethyl-2-(2-amino-4-methylphenyl thio)benzylamine as a Ligand of the Serotonin Transporter with High Affinity and Selectivity , 2003, Journal of Pharmacology and Experimental Therapeutics.
[252] Jan Pruim,et al. 5‐HT1A receptor imaging in the human brain: Effect of tryptophan depletion and infusion on [18F]MPPF binding , 2002 .
[253] Alan A. Wilson,et al. Comparative Evaluation in Nonhuman Primates of Five PET Radiotracers for Imaging the Serotonin Transporters: [11C]McN 5652, [11C]ADAM, [11C]DASB, [11C]DAPA, and [11C]AFM , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[254] Mats Fredrikson,et al. Kinetic Compartment Modeling of [11C]-5-Hydroxy-L-Tryptophan for Positron Emission Tomography Assessment of Serotonin Synthesis in Human Brain , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[255] Julie C Price,et al. Reduced 5-HT2A receptor binding after recovery from anorexia nervosa , 2002, Biological Psychiatry.
[256] Yiyun Huang,et al. Synthesis and pharmacological characterization of a new PET ligand for the serotonin transporter: [11C]5-bromo-2-[2-(dimethylaminomethylphenylsulfanyl)]phenylamine ([11C]DAPA). , 2002, Nuclear medicine and biology.
[257] S. Obayashi,et al. Synthesis and preliminary PET study of the 5‐HT7 receptor antagonist [11C]DR4446 , 2002 .
[258] Paul J. Harrison,et al. 5‐HT6 receptor binding sites in schizophrenia and following antipsychotic drug administration: Autoradiographic studies with [125I]SB‐258585 , 2002, Synapse.
[259] N. Guo,et al. Pharmacokinetics and brain distribution in non human primate of R(-)[123I]DOI, A 5HT(2A/2C) serotonin agonist. , 2002, Nuclear medicine and biology.
[260] Sylvain Houle,et al. In vitro and in vivo characterisation of [11C]-DASB: a probe for in vivo measurements of the serotonin transporter by positron emission tomography. , 2002, Nuclear medicine and biology.
[261] John Hilton,et al. Comparison of (+)-11C-McN5652 and 11C-DASB as Serotonin Transporter Radioligands Under Various Experimental Conditions , 2002 .
[262] R. Baldessarini,et al. Synthesis, receptor potency, and selectivity of halogenated diphenylpiperidines as serotonin 5-HT2A ligands for PET or SPECT brain imaging. , 2002, Journal of medicinal chemistry.
[263] R. Gunn,et al. The PET radioligand [carbonyl-(11)C]desmethyl-WAY-100635 binds to 5-HT(1A) receptors and provides a higher radioactive signal than [carbonyl-(11)C]WAY-100635 in the human brain. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[264] Roger N. Gunn,et al. A Database of [11C]WAY-100635 Binding to 5-HT1A Receptors in Normal Male Volunteers: Normative Data and Relationship to Methodological, Demographic, Physiological, and Behavioral Variables , 2002, NeuroImage.
[265] Abraham Z Snyder,et al. Greater loss of 5-HT(2A) receptors in midlife than in late life. , 2002, The American journal of psychiatry.
[266] D. Middlemiss,et al. [3 H]-SB-269970 radiolabels 5-HT7 receptors in rodent, pig and primate brain tissues , 2002, Neuropharmacology.
[267] J. Sandell,et al. PET-examination and metabolite evaluation in monkey of [(11)C]NAD-299, a radioligand for visualisation of the 5-HT(1A) receptor. , 2002, Nuclear medicine and biology.
[268] Jan Pruim,et al. 5-HT(1A) receptor imaging in the human brain: effect of tryptophan depletion and infusion on [(18)F]MPPF binding. , 2002, Synapse.
[269] Alan A. Wilson,et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. , 2001, The American journal of psychiatry.
[270] Alan A. Wilson,et al. Positron Emission Tomography Quantification of [11C]-DASB Binding to the Human Serotonin Transporter: Modeling Strategies , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[271] Katarina Varnäs,et al. Autoradiographic mapping of 5-HT1B and 5-HT1D receptors in the post mortem human brain using [3H]GR 125743 , 2001, Brain Research.
[272] Mirko Diksic,et al. Study of the brain serotonergic system with labeled α‐methyl‐l‐tryptophan , 2001 .
[273] M. Travis,et al. In vivo 5-HT2A receptor blockade by quetiapine , 2001, Psychopharmacology.
[274] D. Holt,et al. Analyses of [18F]altanserin bolus injection PET data. I: Consideration of radiolabeled metabolites in baboons , 2001, Synapse.
[275] Gwenn S. Smith,et al. Analyses of [18F]altanserin bolus injection PET data. II: Consideration of radiolabeled metabolites in humans , 2001, Synapse.
[276] K. Krobert,et al. The cloned human 5-HT7 receptor splice variants: a comparative characterization of their pharmacology, function and distribution , 2001, Naunyn-Schmiedeberg's Archives of Pharmacology.
[277] R Hen,et al. Human 5-HT(5) receptors: the 5-HT(5A) receptor is functional but the 5-HT(5B) receptor was lost during mammalian evolution. , 2001, European journal of pharmacology.
[278] Robert B. Innis,et al. Reproducibility of in vivo brain measures of 5-HT2A receptors with PET and [18F]deuteroaltanserin , 2001, Psychiatry Research: Neuroimaging.
[279] J. Staley,et al. Comparison of [(18)F]altanserin and [(18)F]deuteroaltanserin for PET imaging of serotonin(2A) receptors in baboon brain: pharmacological studies. , 2001, Nuclear medicine and biology.
[280] H. Wikström,et al. New halogenated [11C]WAY analogues, [11C]6FPWAY and [11C]6BPWAY--radiosynthesis and assessment as radioligands for the study of brain 5-HT1A receptors in living monkey. , 2001, Nuclear medicine and biology.
[281] K. Laere,et al. Decreased frontal serotonin 5-HT2a receptor binding index in deliberate self-harm patients , 2001, European Journal of Nuclear Medicine.
[282] H. Wikström,et al. Radioligands for the study of brain 5-HT1A receptors in vivo. , 2001, Progress in medicinal chemistry.
[283] B. Johannsen,et al. A novel technetium-99m radioligand for the 5-HT1A receptor derived from desmethyl-WAY-100635 (DWAY) , 2001, European Journal of Nuclear Medicine and Molecular Imaging.
[284] Jan Passchier,et al. Visualisation of serotonin-1A (5-HT1A) receptors in the central nervous system , 2001, European Journal of Nuclear Medicine.
[285] M Diksic,et al. Study of the brain serotonergic system with labeled α‐methyl‐l‐tryptophan , 2001, Journal of neurochemistry.
[286] G. Sedvall,et al. Autoradiographic localization of 5‐HT2A receptors in the human brain using [3H]M100907 and [11C]M100907 , 2000, Synapse.
[287] W Vaalburg,et al. Influence of P-glycoprotein on brain uptake of [18F]MPPF in rats. , 2000, European journal of pharmacology.
[288] J. Seibyl,et al. Equilibrium modeling of 5-HT(2A) receptors with [18F]deuteroaltanserin and PET: feasibility of a constant infusion paradigm. , 2000, Nuclear medicine and biology.
[289] W Vaalburg,et al. In vivo delineation of 5-HT1A receptors in human brain with [18F]MPPF. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[290] L. San,et al. Altered 5-HT2A binding sites and second messenger inositol trisphosphate (IP3) levels in hippocampus but not in frontal cortex from depressed suicide victims , 2000, Psychiatry Research: Neuroimaging.
[291] Alan A. Wilson,et al. Imaging the serotonin transporter with positron emission tomography: initial human studies with [11C]DAPP and [11C]DASB , 2000, European Journal of Nuclear Medicine.
[292] D. Middlemiss,et al. Characterization of [125I]‐SB‐258585 binding to human recombinant and native 5‐HT6 receptors in rat, pig and human brain tissue , 2000 .
[293] S. Stahl,et al. Serotonin and anxiety: current models , 2000, International clinical psychopharmacology.
[294] J. Passchier,et al. Quantitative imaging of 5-HT(1A) receptor binding in healthy volunteers with [(18)f]p-MPPF. , 2000, Nuclear medicine and biology.
[295] S. Houle,et al. Imaging the 5-HT(1A) receptors with PET: WAY-100635 and analogues. , 2000, Nuclear medicine and biology.
[296] W C Eckelman,et al. PET evaluation of [(18)F]FCWAY, an analog of the 5-HT(1A) receptor antagonist, WAY-100635. , 2000, Nuclear medicine and biology.
[297] W C Eckelman,et al. Kinetic Analysis of the 5-HT2A Ligand [11C]MDL 100,907 , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[298] M. Iyo,et al. Serotonin 5-HT2 receptors in schizophrenic patients studied by positron emission tomography. , 2000, Life Science.
[299] P. Bonaventure,et al. Mapping of serotonin 5‐HT4 receptor mRNA and ligand binding sites in the post‐mortem human brain , 2000, Synapse.
[300] M. Laruelle. Imaging Synaptic Neurotransmission with in Vivo Binding Competition Techniques: A Critical Review , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[301] D. Charney,et al. PET quantification of 5-HT2A receptors in the human brain: a constant infusion paradigm with [18F]altanserin. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[302] Peter Herscovitch,et al. The Suitability of [11C]-α-Methyl-L-tryptophan as a Tracer for Serotonin Synthesis: Studies With Dual Administration of [11C] and [14C] Labeled Tracer , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[303] O. Muzik,et al. α[C-11]Methyl-l-Tryptophan PET Maps Brain Serotonin Synthesis and Kynurenine Pathway Metabolism , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[304] R. Kerwin,et al. In vivo serotonin 5-HT(2A) receptor occupancy and quetiapine. , 2000, The American journal of psychiatry.
[305] D. Middlemiss,et al. Characterization of [(125)I]-SB-258585 binding to human recombinant and native 5-HT(6) receptors in rat, pig and human brain tissue. , 2000, British journal of pharmacology.
[306] Sylvain Houle,et al. Radiosynthesis of carbon‐11 labelled N‐methyl‐2‐(arylthio)benzylamines: potential radiotracers for the serotonin reuptake receptor , 1999 .
[307] B. Mulsant,et al. PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. , 1999, The American journal of psychiatry.
[308] O B Paulson,et al. No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. , 1999, Diabetes.
[309] Comparative in vivo study of iodine‐123‐labeled β‐cit and nor‐β‐cit binding to serotonin transporters in rat brain , 1999, Synapse.
[310] P. Acton,et al. Single-photon emission tomography imaging of serotonin transporters in the nonhuman primate brain with [123I]ODAM , 1999, European Journal of Nuclear Medicine.
[311] D. Charney,et al. Characterization of radioactive metabolites of 5-HT2A receptor PET ligand [18F]altanserin in human and rodent. , 1999, Nuclear medicine and biology.
[312] Trevor Sharp,et al. A review of central 5-HT receptors and their function , 1999, Neuropharmacology.
[313] P. Acton,et al. Characterization of [123I]IDAM as a novel single-photon emission tomography tracer for serotonin transporters , 1999, European Journal of Nuclear Medicine.
[314] S. Kapur,et al. Prefrontal cortex 5-HT2 receptors in depression: an [18F]setoperone PET imaging study. , 1999, The American journal of psychiatry.
[315] L. Descarries,et al. Cellular and subcellular distribution of the serotonin 5‐HT2A receptor in the central nervous system of adult rat , 1999, The Journal of comparative neurology.
[316] A. Luxen,et al. Biochemical and Autoradiographic Measurements of Brain Serotonin Synthesis Rate in the Freely Moving Rat , 1999, Journal of neurochemistry.
[317] W C Eckelman,et al. Development of fluorine-18-labeled 5-HT1A antagonists. , 1999, Journal of medicinal chemistry.
[318] C. Halldin,et al. Different brain radioactivity curves in a PET study with [11C]beta-CIT labelled in two different positions. , 1999, Nuclear medicine and biology.
[319] P. Acton,et al. A new single-photon emission computed tomography imaging agent for serotonin transporters: [123I]IDAM, 5-iodo-2-((2-((dimethylamino)methyl)phenyl)thio)benzyl alcohol. , 1999, Journal of medicinal chemistry.
[320] G. Sedvall,et al. Radiosynthesis and autoradiographic evaluation of [11C]NAD-299, a radioligand for visualization of the 5-HT1A receptor. , 1999, Nuclear medicine and biology.
[321] I. Coupar,et al. [3H]‐Mesulergine labels 5‐HT7 sites in rat brain and guinea‐pig ileum but not rat jejunum , 1999, British journal of pharmacology.
[322] J. Wernicke,et al. A noradrenergic and serotonergic hypothesis of the linkage between epilepsy and affective disorders. , 1999, Critical reviews in neurobiology.
[323] P. Acton,et al. Single-photon emission tomography imaging of serotonin transporters in the nonhuman primate brain with [(123)I]ODAM. , 1999, European journal of nuclear medicine.
[324] P. Acton,et al. Single-photon emission tomography imaging of serotonin transporters in the non-human primate brain with the selective radioligand [(123)I]IDAM. , 1999, European journal of nuclear medicine.
[325] D. Lovinger,et al. Characterization of (S)-des-4-amino-3-[125I]iodozacopride ([125I]DAIZAC), a selective high-affinity radioligand for 5-hydroxytryptamine3 receptors. , 1999, The Journal of pharmacology and experimental therapeutics.
[326] Chris Baeken,et al. 123I-5-I-R91150, a new single-photon emission tomography ligand for 5-HT2A receptors: influence of age and gender in healthy subjects , 1998, European Journal of Nuclear Medicine.
[327] Charles F. Reynolds,et al. Reduced binding of [ 18 F ]altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction , 1998, Brain Research.
[328] E. Jerning,et al. Receptor binding characteristics of [3H]NAD-299, a new selective 5-HT1A receptor antagonist. , 1998, European journal of pharmacology.
[329] Roger N. Gunn,et al. Tracer Kinetic Modeling of the 5-HT1AReceptor Ligand [carbonyl-11C]WAY-100635 for PET , 1998, NeuroImage.
[330] D. Hommer,et al. Brain Serotonin Synthesis Rates in Rhesus Monkeys Determined by [11C;[alpha;-Methyl-L-Tryptophan and Positron Emission Tomography Compared to CSF 5-Hydroxyindole-3-Acetic Acid Concentrations , 1998, Neuropsychopharmacology.
[331] S. Ametamey,et al. 123I-MSP and F[11C]MSP: new selective 5-HT2A receptor radiopharmaceuticals for in vivo studies of neuronal 5-HT2 serotonin receptors. Synthesis, in vitro binding study with unlabelled analogues and preliminary in vivo evaluation in mice. , 1998, Life sciences.
[332] M. Palacín,et al. Molecular biology of mammalian plasma membrane amino acid transporters. , 1998, Physiological reviews.
[333] J. Palacios,et al. [3H]MDL100,907 labels 5-HT2A serotonin receptors selectively in primate brain , 1998, Neuropharmacology.
[334] R. Kerwin,et al. 5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine , 1998, British Journal of Psychiatry.
[335] J. Baron,et al. Synthesis and biological investigations of [18F]MR18445, a 5-HT3 receptor partial agonist. , 1998, Bioorganic & medicinal chemistry.
[336] D Comar,et al. High-yield radiosynthesis and preliminary in vivo evaluation of p-[18F]MPPF, a fluoro analog of WAY-100635. , 1998, Nuclear medicine and biology.
[337] J. Martinot,et al. Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. , 1998, The American journal of psychiatry.
[338] P. Grasby,et al. Characterisation of the appearance of radioactive metabolites in monkey and human plasma from the 5-HT1A receptor radioligand, [carbonyl-11C]WAY-100635--explanation of high signal contrast in PET and an aid to biomathematical modelling. , 1998, Nuclear medicine and biology.
[339] H. Wikström,et al. [carbonyl-11C]Desmethyl-WAY-100635 (DWAY) is a potent and selective radioligand for central 5-HT1A receptors in vitro and in vivo , 1998, European Journal of Nuclear Medicine.
[340] H. Kung,et al. Isoindol-1-one analogues of 4-(2'-methoxyphenyl)-1-[2'-[N-(2"-pyridyl)-p-iodobenzamido]ethyl]pipera zine (p-MPPI) as 5-HT1A receptor ligands. , 1998, Journal of medicinal chemistry.
[341] Otto Muzik,et al. Human brain serotonin synthesis capacity measured in vivo with α‐[C‐11]methyl‐L‐tryptophan , 1998 .
[342] J. Baron,et al. [11C]S21007, a putative partial agonist for 5-HT3 receptors PET studies. Rat and primate in vivo biological evaluation. , 1997, Life sciences.
[343] C. Halldin,et al. PET imaging of central 5-HT2A receptors with carbon-11-MDL 100,907. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[344] O Muzik,et al. Human brain serotonin synthesis capacity measured in vivo with alpha-[C-11]methyl-L-tryptophan. , 1998, Synapse.
[345] J. Karhu,et al. Iodine-123 labeled nor-β-CIT as a potential tracer for serotonin transporter imaging in the human brain with single-photon emission tomography , 1997, European Journal of Nuclear Medicine.
[346] S. Houle,et al. Imaging 5‐HT1A receptors with positron emission tomography: Initial human studies with [11C]CPC‐222 , 1997, Nuclear medicine communications.
[347] G McKay,et al. PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia. , 1997, The American journal of psychiatry.
[348] J. Palacios,et al. Selective visualization of rat brain 5-HT2A receptors by autoradiography with [3H]MDL 100,907 , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.
[349] Gerhard Gründer,et al. Time Course of 5-HT2A Receptor Occupancy in the Human Brain after a Single Oral Dose of the Putative Antipsychotic Drug MDL 100,907 Measured by Positron Emission Tomography , 1997, Neuropsychopharmacology.
[350] E. Corruble,et al. Frontal 5-HT2A receptors studied in depressive patients during chronic treatment by selective serotonin reuptake inhibitors , 1997, Psychopharmacology.
[351] J. Palacios,et al. Characterization of human serotonin 1D and 1B receptors using [ 3H]-GR-125743, a novel radiolabelled serotonin 5HT1D/1B receptor antagonist , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.
[352] P. Sáiz,et al. PET neuroimaging with [11C]venlafaxine: serotonin uptake inhibition, biodistribution and binding in living pig brain , 1997, European Neuropsychopharmacology.
[353] S. Stone-Elander,et al. N-methylquipazine: carbon-11 labelling of the 5-HT3 agonist and in vivo evaluation of its biodistribution using PET. , 1997, Nuclear medicine and biology.
[354] Paul J. Harrison,et al. [3H]WAY–100635 for 5–HT1A receptor autoradiography in human brain: a comparison with [3H]8–OH–DPAT and demonstration of increased binding in the frontal cortex in schizophrenia , 1997, Neurochemistry International.
[355] O Muzik,et al. Analysis of [C-11]Alpha-Methyl-Tryptophan Kinetics for the Estimation of Serotonin Synthesis Rate In Vivo , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[356] J. Leysen,et al. Preclinical evaluation of [123I]R93274 as a SPECT radiotracer for imaging 5-HT2A receptors. , 1997, European journal of pharmacology.
[357] H. Kung,et al. p‐[18F]‐MPPF: A potential radioligand for PET studies of 5‐HT1A receptors in humans , 1997, Synapse.
[358] H. Wikström,et al. Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]WAY-100635 , 1997, Brain Research.
[359] A Schotte,et al. Autoradiographic mapping of 5-HT1B- and 5-HT1D receptors in human brain using [3H]alniditan, a new radioligand. , 1997, Receptors & channels.
[360] J. Leysen,et al. Initial evaluation of 123I-5-I-R91150, a selective 5-HT2A ligand for single-photon emission tomography, in healthy human subjects. , 1997, European Journal of Nuclear Medicine.
[361] Y. Samson,et al. Post-stroke changes in cortical 5-HT2 serotonergic receptors. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[362] N. Barnes,et al. Autoradiographic distribution of [3H]-(S)-zacopride-labelled 5-HT3 receptors in human brain , 1996, Journal of the Neurological Sciences.
[363] S. Kushner,et al. In vivo SPECT imaging of 5‐HT1A receptors with [123I] p‐MPPI in nonhuman primates , 1996, Synapse.
[364] N. Barnes,et al. Distribution and characterisation of the [3H](S)-zacopride labelled 5-HT3 receptor in pig forebrain , 1996, Brain Research.
[365] H. Kung,et al. Short Communication New 5‐HT1A receptor antagonist: [3H]p‐MPPF , 1996, Synapse.
[366] P. Grasby,et al. Characterization of the radioactive metabolites of the 5-HT1A receptor radioligand, [O-methyl-11C]WAY-100635, in monkey and human plasma by HPLC: comparison of the behaviour of an identified radioactive metabolite with parent radioligand in monkey using PET. , 1996, Nuclear medicine and biology.
[367] M. Kiyosawa,et al. Synthesis and evaluation of 5-HT3 receptor antagonist [11C]KF17643. , 1996, Nuclear medicine and biology.
[368] L. Barré,et al. Synthesis of [11C]‐S21007 a novel 5HT3 partial agonist as a potential tracer for PET studies , 1996 .
[369] A. Lammertsma,et al. Development of central 5-HT2A receptor radioligands for PET: comparison of [3H]RP 62203 and [3H]SR 46349B kinetics in rat brain. , 1996, Nuclear medicine and biology.
[370] C. Halldin,et al. [11C]MDL 100907, a radioligland for selective imaging of 5-HT(2A) receptors with positron emission tomography. , 1996, Life sciences.
[371] J. Baron,et al. Specific in vivo binding in the rat brain of [18F]RP 62203: a selective 5-HT2A receptor radioligand for positron emission tomography. , 1996, Nuclear medicine and biology.
[372] Allan Fletcher,et al. Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist , 1995, Behavioural Brain Research.
[373] J. Roberts,et al. Localization of serotonin-4 receptors in the striatonigral pathway in rat brain , 1995, Neuroscience.
[374] J. Leysen,et al. Evaluation of radioiodo-4-amino-N-[1-[3-(4-fluorophenoxy)-propyl]-4- methyl-4-piperidinyl]-5-iodo-2-methoxybenzamide as a potential 5HT2 receptor tracer for SPE(C)T. , 1995, Nuclear medicine and biology.
[375] G. Sedvall,et al. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. , 1995, The American journal of psychiatry.
[376] A Malizia,et al. First delineation of 5-HT1A receptors in human brain with PET and [11C]WAY-100635. , 1995, European journal of pharmacology.
[377] M. Senda,et al. Synthesis of 5-HT3 receptor antagonists, [11C]Y-25130 and [11C]YM060. , 1995, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[378] P. Maquet,et al. Serotonin 5HT2 Receptor Imaging in the Human Brain Using Positron Emission Tomography and a New Radioligand, [18F]Altanserin: Results in Young Normal Controls , 1995, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[379] A. Beaudet,et al. In vivo‐synthesized radioactively labelled α‐methyl serotonin as a selective tracer for visualization of brain serotonin neurons , 1995, Synapse.
[380] R. Eglen,et al. The pharmacology and distribution of human 5‐hydroxytryptamine2B (5‐HT2b) receptor gene products: comparison with 5‐HT2a and 5‐HT2c receptors , 1995, British journal of pharmacology.
[381] Zsolt Szabo,et al. Positron emission tomography imaging of serotonin transporters in the human brain using [11C](+)McN5652 , 1995, Synapse.
[382] S. Pappatà,et al. 5HT2 Receptors in Cerebral Cortex of Migraineurs Studied Using PET and 18F-Fluorosetoperone , 1995, Cephalalgia : an international journal of headache.
[383] M. Hamon,et al. Selective in vivo labelling of brain 5-HT1A receptors by [3H]WAY 100635 in the mouse. , 1994, European journal of pharmacology.
[384] H. Kung,et al. In vivo binding of [123I]4‐(2′‐methoxy phenyl)‐1‐[2′‐(N‐2″‐pyridinyl)‐P‐iodobenzamido‐]ethyl‐piperazine, p‐MPPI, to 5‐HT1A receptors in rat brain , 1994, Synapse.
[385] J. Leysen,et al. Radiosynthesis of a new radioiodinated ligand for serotonin‐5HT2‐receptors, a promising tracer for γ‐emission tomography , 1994 .
[386] E. Wong,et al. Quantitative autoradiography of 5-HT4 receptors in brains of three species using two structurally distinct radioligands, [3H]GR113808 and [3H]BIMU-1 , 1994, Neuropharmacology.
[387] D. Nelson,et al. Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine2B receptor. , 1994, Molecular pharmacology.
[388] P P Humphrey,et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). , 1994, Pharmacological reviews.
[389] I. Martin,et al. Molecular biology of 5-HT receptors , 1994, Neuropharmacology.
[390] M. Mintun,et al. [11C]WAY 100635: a radioligand for imaging 5-HT1A receptors with positron emission tomography. , 1994, Life sciences.
[391] N. Barnes,et al. Distribution and characterization of the [3H]granisetron-labelled 5-HT3 receptor in the human forebrain , 1993, Neuropharmacology.
[392] J. Bockaert,et al. [3H]-GR113808 labels 5-HT4 receptors in the human and guinea-pig brain. , 1993, Neuroreport.
[393] J. Kleinman,et al. Serotonin 5-HT3 receptors in schizophrenia: a postmortem study of the amygdala , 1993, Brain Research.
[394] C Crouzel,et al. Loss of brain 5-HT2 receptors in Alzheimer's disease. In vivo assessment with positron emission tomography and [18F]setoperone. , 1993, Brain : a journal of neurology.
[395] Marc Laruelle,et al. SPECT imaging of dopamine and serotonin transporters with [123I]β‐CIT: Pharmacological characterization of brain uptake in nonhuman primates , 1993, Synapse.
[396] J. Baron,et al. Positron emission tomographic studies of [11C]MDL 72222, a potential 5-HT3 receptor radioligand: Distribution, kinetics and binding in the brain of the baboon , 1993, Neuropharmacology.
[397] B. Långström,et al. Uptake and utilization of [beta-11C] 5-hydroxytryptophan in human brain studied by positron emission tomography , 1992, Psychiatry Research: Neuroimaging.
[398] B. Hoffman,et al. Molecular pharmacological differences in the interaction of serotonin with 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors. , 1992, Molecular pharmacology.
[399] G. Sedvall,et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. , 1992, Archives of general psychiatry.
[400] M. Teitler,et al. Quantitative autoradiography of 5-CT-sensitive (5-HT1D) and 5-CT-insensitive (5-HT1E) serotonin receptors in human brain , 1992, Neuroscience Letters.
[401] D. Girdlestone,et al. Pharmacological characterization of RP 62203, a novel 5‐hydroxytryptamine 5‐HT2 receptor antagonist , 1992, British journal of pharmacology.
[402] C. Lemaire,et al. Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[403] M. Breeding,et al. (+)Lysergic acid diethylamide, but not its nonhallucinogenic congeners, is a potent serotonin 5HT1C receptor agonist. , 1991, The Journal of pharmacology and experimental therapeutics.
[404] J. Perlmutter,et al. Central serotonergic S2 binding in Papio anubis measured in vivo with N-ω-[18 F]fluoroethylketanserin and PET , 1991, Neuroscience Letters.
[405] P. Plenge,et al. Regional distribution of the serotonin transport complex in human brain, identified with 3H-Paroxetine, 3H-Citalopram and 3H-Imipramine , 1990, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[406] R. Glennon,et al. Autoradiographic characterization of (+-)-1-(2,5-dimethoxy-4-[125I] iodophenyl)-2-aminopropane ([125I]DOI) binding to 5-HT2 and 5-HT1c receptors in rat brain. , 1990, The Journal of pharmacology and experimental therapeutics.
[407] Gavin Kilpatrick,et al. 5‐HT3 receptors , 1990, Medicinal research reviews.
[408] C Crouzel,et al. A Method for the In Vivo Investigation of the Serotonergic 5‐HT2 Receptors in the Human Cerebral Cortex Using Positron Emission Tomography and 18F‐Labeled Setoperone , 1990, Journal of neurochemistry.
[409] M. Diksic,et al. A New Method to Measure Brain Serotonin Synthesis in vivo. I. Theory and Basic Data for a Biological Model , 1990 .
[410] J. Saavedra,et al. Autoradiographic localization of 5HT2 receptors in rat brain using [125I]-DOI, a selective psychotomimetic radioligand , 1989, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[411] T. Jessell,et al. 5-HT1c receptor is a prominent serotonin receptor subtype in the central nervous system. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[412] Yasuyoshi Watanabe,et al. Syntheses of β-11C-labelled L-tryptophan and 5-hydroxy-L-tryptophan using a multi-enzymatic reaction route , 1989 .
[413] D. Wong,et al. Synthesis and in vivo characterization of D-(+)-(N1-[11C]methyl)-2-Br-LSD: a radioligand for positron emission tomographic studies of serotonin 5-HT2 receptors. , 1989, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.
[414] J. Palacios,et al. Autoradiography of antidepressant binding sites in the human brain: localization using [3h]imipramine and [3h]paroxetine , 1988, Neuroscience.
[415] A. Doenicke,et al. POSSIBLE BENEFIT OF GR43175, A NOVEL 5-HT1-LIKE RECEPTOR AGONIST, FOR THE ACUTE TREATMENT OF SEVERE MIGRAINE , 1988, The Lancet.
[416] C Crouzel,et al. [18F]setoperone: a new high-affinity ligand for positron emission tomography study of the serotonin-2 receptors in baboon brain in vivo. , 1988, European journal of pharmacology.
[417] R. Glennon,et al. Iodine-125 labeled 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane: an iodinated radioligand that specifically labels the agonist high-affinity state of 5-HT2 serotonin receptors , 1988 .
[418] R. Glennon,et al. [125I]-1-(2,5-dimethoxy-4-iodophenyl)-2-amino-propane: an iodinated radioligand that specifically labels the agonist high-affinity state of 5-HT2 serotonin receptors. , 1988, Journal of medicinal chemistry.
[419] J. Palacios,et al. Serotonin receptors in the human brain—IV. Autoradiographic mapping of serotonin-2 receptors , 1987, Neuroscience.
[420] M. Ticku,et al. Central cardiovascular effects of baclofen in spontaneously hypertensive rats. , 1987, Life sciences.
[421] M. Kuhar,et al. In vivo binding of 3H-N-methylspiperone to dopamine and serotonin receptors. , 1987, Life sciences.
[422] O. Inoue,et al. Synthesis and evaluation of [11C]cyanoimipramine. , 1987, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.
[423] Alan A. Wilson,et al. Localization of serotonin 5‐HT2 receptors in living human brain by positron emission tomography using N1‐([11C]‐methyl)‐2‐BR‐LSD , 1987, Synapse.
[424] J M Links,et al. 3H-3-N-methylspiperone labels D2 dopamine receptors in basal ganglia and S2 serotonin receptors in cerebral cortex , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[425] J. Palacios,et al. Serotonin receptors in the human brain. II. Characterization and autoradiographic localization of 5-HT1C and 5-HT2 recognition sites , 1986, Brain Research.
[426] Y. Agid,et al. [In vivo study of central serotoninergic receptors in man using positron tomography]. , 1985, Revue neurologique.
[427] M. Folstein,et al. EFFECTS OF AGE ON DOPAMINE AND SEROTONIN RECEPTORS MEASURED BY POSITRON TOMOGRAPHY IN THE LIVING HUMAN BRAIN , 1984, Science.
[428] J. Goble,et al. Measurement of Blood—Brain Barrier Permeability with Positron Emission Tomography and [68Ga]EDTA , 1984, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[429] J. Links,et al. Imaging dopamine receptors in the human brain by positron tomography. , 1984, Science.
[430] R H Huesman,et al. Regional Cerebral Metabolic Alterations in Dementia of the Alzheimer Type: Positron Emission Tomography with [1818] Fluorodeoxyglucose , 1983, Journal of computer assisted tomography.
[431] S. Gershon,et al. Tritiated imipramine binding sites are decreased in the frontal cortex of suicides. , 1982, Science.
[432] E. Hoffman,et al. TOMOGRAPHIC MEASUREMENT OF LOCAL CEREBRAL GLUCOSE METABOLIC RATE IN HUMANS WITH (F‐18)2‐FLUORO-2‐DEOXY-D‐GLUCOSE: VALIDATION OF METHOD , 1980, Annals of neurology.
[433] T. Budinger,et al. An iodinated catecholamine congener for brain imaging and metabolic studies. , 1978, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[434] N. Kusubov,et al. In vivo human pharmacodynamics of the psychodysleptic 4-Br-2,5-dimethoxyphenylisopropylamine labelled with 82Br or 77Br , 1975, Neuropharmacology.
[435] C HISCOCK,et al. EPIDEMICS OF TYPHOID FEVER. , 1964, Lancet.
[436] J. Kornhuber,et al. Binding kinetics in the human brain , 2022 .